ArticleThe Journal of investigative dermatology2011
Fisetin: a natural fist against melanoma?
Article in The Journal of investigative dermatology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Solid-state studies and antioxidant properties of the γ-cyclodextrin·fisetin inclusion compound.Beilstein journal of organic chemistry · 2017Article
- Targeting drivers of melanoma with synthetic small molecules and phytochemicals.Cancer letters · 2015Review
- Fisetin: a dietary antioxidant for health promotion.Antioxidants & redox signaling · 2013Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Melanoma has now become the subject of targeted therapies, based upon the high prevalence of B-raf mutations in melanoma. However, while initial responses to B-raf inhibitors are impressive, resistance is extremely common, suggesting that melanoma is not addicted to B-raf. In their report, Syed et al. demonstrate that fisetin, a natural product without well established mechanisms, has activity against melanoma. Their report suggests that "nontargeted therapies" need to become part of our armamentarium against melanoma, given that targeted therapies do not target all of the pathways required for melanoma growth.
Indexed as
Identifiers
21566577What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.